Imago Biosciences — EHA 2022 Virtual Investor Event
23 slides from Imago Biosciences's conference presentation, Jun 13, 2022
Slide 1: Virtual Investor Event EHA 2022
VIRTUAL INVESTOR EVENT EHA 2022 11 June 2022 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation and the accompanying oral presentation by Imago BioSciences, Inc. (“Imago,” the “Company,” “we,” “us” or similar terms) contains forward looking statements. These statements may relate to, but are not limited to, the results, conduct, progress and timing of Imago clinical trials, t
Slide 3: What's New at EHA?
What’s New at EHA? Major update on ET program: EHA Apr 29, 2022 Data-Cut vs. ASH Nov 1, 2021 Data-Cut Significant Follow-Up 93% (N=29 > 6 weeks) hematologic remission (HR) at ASH 97% (N=32 ≥ 24 weeks) HR at EHA 81% (N=26) achieved durability (HR ≥ 12 weeks) Preliminary efficacy rate exceeds publishe
Slide 4: Introduction to Bomedemstat
Introduction to Bomedemstat *IMG-7289-CTP-101, IMG-7289-CTP-102, CTP-202 and IMG-7289-CTP-201 Bomedemstat is an irreversible inhibitor of LSD1 Discovered by Imago – COM 2034+ PK and dose-response data support once-daily dosing No apparent penetration across the blood-brain barrier Bomedemstat has be
Slide 5: Strong Rationale for LSD1 Inhibition in MPNs
Malignant Cell Population Strong Rationale for LSD1 Inhibition in MPNs “Activated” Megakaryocytes Reduced by LSD1 inhibition Mutant Hematopoietic Stem Cell Reticulin, Collagen Lowered by LSD1 inhibition Inflammatory Cytokines (e.g., IL-8) Lowered by LSD1 inhibition Growth Factors (e.g., TGFβ1, VEGF,
Slide 6: ET Epidemiology and Market Opportunity for Bomedemstat
US qualitative and quantitative research indicates an opportunity to expand size of 2L market1 Many ET patients receive sub-optimal treatment owing to lack of acceptable second line agents In a large US-based study, 54% of patients on cytoreductive therapy had excess platelets at screening5 Potentia
Slide 7: ET (CTP-201) Study Design
Safety and tolerability Platelet count reduction (≤400 x 109/L) in the absence of thromboembolic events ET (CTP-201) Study Design Primary Endpoints Key Eligibility Criteria Secondary Endpoints Symptom reduction (MPN-SAF TSS) Durability of platelet and WBC count reduction Changes in mutant allele fre
Slide 8: ET Enrollment and Treatment Status
ET Enrollment and Treatment Status 12 Weeks 24 Weeks 48 Weeks 36 Weeks Source: Imago interim, unaudited and ongoing Phase 2 data of Investigational Product; Data cut-off: 29April2022 EOT used for last dose date if available, otherwise last dose date in exposure dataset At time of data cut-off (April
Slide 9: ET Safety and Tolerability Profile
Source: Imago interim, unaudited and ongoing Phase 2 data of Investigational Product; Data cut-off: 29April2022 ET Safety and Tolerability Profile Preferred Term (N=67) Any Grade AEs Grade 3/4 AEs Dysgeusia 28 (42%) N/A Fatigue 17 (25%) 0 Constipation 17 (25%) 1 (2%) Arthralgia 15 (22%) 2 (3%) Throm
Slide 10: ET Baseline Demographics and Disease Characteristics
*Protocol deviation; 1Toxicities including fever, mucocutaneous manifestations or leg ulcers; 2Following a daily dose of ≥3g for at least 3 mo ET Baseline Demographics and Disease Characteristics Characteristic N = 67 Median age (range) 67 (42 – 92) Male 28 (42%) Mean blood counts (range) WBC Haemog
Slide 11: ET Primary Objective: Reduction in Platelet Count
ET Primary Objective: Reduction in Platelet Count Source Imago interim, unaudited and ongoing Phase 2 data of Investigational Product Mean Platelet Count (±95% CI) N=67 *Includes only patients reaching at least 24 weeks, ie not the ITT population S=Screening, B = Last non-missing value closest to Da
Slide 12: ET Platelet Count and Mutant Allele Frequency Response
ET Platelet Count and Mutant Allele Frequency Response Source Imago interim, unaudited and ongoing Phase 2 data of Investigational Product Mutation No. of Patients* Mean Baseline Platelet Count (x109/L) Platelet Count Response (%)# All Pts 53 818 JAK2V617F 27 741 100% CALR 19 988 93% MPL 2 1018 100%
Slide 13: ET Lowers WBCs and Maintains Haemoglobin Levels
ET Lowers WBCs and Maintains Haemoglobin (Hb) levels Mean WBC (±95% CI) N=67 Source Imago interim, unaudited and ongoing Phase 2 data of Investigational Product Mean Hb (±95% CI) N=67 S=Screening, B = Last non-missing value closest to Day 1 Weeks on Treatment White Blood Count (x109/L) Weeks on Trea
Slide 14: ET Changes in Individual Components of the MPN-SAF TSS
Source Imago interim, unaudited and ongoing Phase 2 data of Investigational Product ET Changes in Individual Components of the MPN-SAF TSS Significant improvements in symptoms with the greatest improvement in fatigue, the most prevalent symptom in patients with ET.
Slide 15: Conclusions of the ET Study
Conclusions of the ET Study Bomedemstat (IMG-7289) is generally well tolerated in patients with ET Majority of AEs were low-grade Bomedemstat as monotherapy demonstrates significant clinical activity: Normalization of platelet and WBC counts while maintaining hemoglobin Symptomatic improvement for s
Slide 16: MF Haemoglobin Changes
Source: Imago interim, unaudited and ongoing Phase 2 data of Investigational Product MF Haemoglobin Changes Change in Haemoglobin in Transfusion-Independent Patients At Week 12, in patients (N=41) transfusion-independent^ at baseline: 90% (37) Stable Hb or Improved 44% (18) Patients had an increase
Slide 17: MF Change in Bone Marrow Fibrosis Scores
Source: Imago interim, unaudited and ongoing Phase 2 data of Investigational Product MF Change in Bone Marrow Fibrosis Scores Case Study: Subject 060-109 is a 58-year-old male with high-risk Post-ET myelofibrosis who was previously treated with thalidomide and ruxolitinib. The patient received bomed
Slide 18: MF Cytokine and MAF Changes
*69 patients provided post baseline samples for sequencing, includes all available samples including those post end of treatment net negative change across all 261 genes and alleles, calculated per patient MF Cytokine and MAF Changes CCL5 d0 levels in normal range; reduction <50% CCL5 d0 levels in n
Slide 19: Bomedemstat Has Greatest Impact on ASXL1-Mutant Clones
MF Bomedemstat has greatest impact on ASXL1-mutant clones Gene SumLog10Changes #cases Sumlog10changes = the sum of the log changes for all alleles in all patients for each of the selected genes (subset of the 261 gene panel); # alleles = total mutant allele determinations for the specified gene (may
Slide 20: Overall Clinical Activity of Bomedemstat
Overall Clinical Activity of Bomedemstat Bomedemstat (IMG-7289) is generally well tolerated in all patients 200+ patients with AML, MDS, MF and ET treated to date Majority of AEs have been low-grade; few related SAEs Bomedemstat as monotherapy demonstrates significant clinical activity: Dosing titra
Slide 21: Development History and Plans
CTP-101 – R/R AML/MDS study completed CTP-102 Advanced MF – on-study patients all enrolled in Extension study (CTP-202) after 1 year CTP-103 Food Effect – completed CTP-104 Mass Balance – completed CTP-105 DDI – FPFV planned for 2H2022 CTP-201 2L ET – fully enrolled, ongoing – on-study patients enro
Slide 22: Conclusions
Conclusions Bomedemstat has been generally well-tolerated in MF and ET patients Shown high level of activity on platelets, WBCs, and symptom improvement The P3 patient population will be very similar to those in the P2 Alignment with the FDA, subject to EOP2 meeting, on the composite primary endpoin
Slide 23: Imago BioSciences – Thank You
IMAGO BIOSCIENCES THANK YOU